Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun 8:5:97-107.
doi: 10.2147/PTT.S63127. eCollection 2015.

Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability

Christina Rogalski  1
Affiliations
Review

Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability

Christina Rogalski. Psoriasis (Auckl). .

Abstract

Background: One of the advances in the treatment of plaque-type psoriasis is combined local therapy with calcipotriol and betamethasone. To provide both ingredients in a two-compound product, efforts have been made to unite calcipotriol and betamethasone because they are usually inactivated when present in the same formulation. This aspect was resolved when carefully designed vehicle components were invented (gel and ointment). This article reviews the efficacy, safety, and patient acceptability of calcipotriol/betamethasone dipropionate.

Methods: A literature search of all articles published until February 2015 was performed, including the largest medical databases. The search strategy for evaluating the main topics of this review - efficacy, safety, and patient acceptability - was defined before checking the publications.

Results: Seventy references were found and checked for relevance. For efficacy, the proportion of patients whose psoriasis improved was always significantly higher in the two-compound group compared to the group treated with the individual substances. In the context of safety, the fixed combination was generally associated with a lower risk of adverse events. In terms of patient acceptability, the fixed combination led to a significant improvement in quality of life. The two-compound product was more convenient to handle and time saving compared to former treatments.

Conclusion: Calcipotriol/betamethasone dipropionate in a fixed combination is an effective and well-tolerated medication in mild-to-moderate psoriasis of body and scalp and, in addition, is an evidence-based treatment modality.

Keywords: calcipotriol/betamethasone; efficacy; fixed combination; psoriasis; safety; two-compound medication.

PubMed Disclaimer

Conflict of interest statement

Disclosure The author reports no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of the publication selection process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol. 1997;37(3 pt 2):S55–S58. - PubMed
    1. Reich K, Bewley A. What is new in topical therapy for psoriasis? J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):15–20. - PubMed
    1. Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;3:CD005028. - PMC - PubMed
    1. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20(4):465–471. - PubMed
    1. White S, Vender R, Thaçi D, et al. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol. 2006;7(3):177–184. - PubMed

LinkOut - more resources